Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast Cancer
NCT05086731 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 33
Last updated 2025-06-17
Summary
This clinical trial evaluates the feasibility and acceptability of a mobile health device in improving oral chemotherapy adherence in women with triple negative breast cancer that has not spread to other places in the body (non-metastatic). A mobile health device, called SMRxT smart pill bottle may help doctors to remind patients to take medicine on time and monitor their symptoms.
Conditions
- Anatomic Stage I Breast Cancer AJCC v8
- Anatomic Stage IA Breast Cancer AJCC v8
- Anatomic Stage IB Breast Cancer AJCC v8
- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage IIA Breast Cancer AJCC v8
- Anatomic Stage IIB Breast Cancer AJCC v8
- Anatomic Stage III Breast Cancer AJCC v8
- Anatomic Stage IIIA Breast Cancer AJCC v8
- Anatomic Stage IIIB Breast Cancer AJCC v8
- Anatomic Stage IIIC Breast Cancer AJCC v8
- Localized Breast Carcinoma
- Prognostic Stage I Breast Cancer AJCC v8
- Prognostic Stage IA Breast Cancer AJCC v8
- Prognostic Stage IB Breast Cancer AJCC v8
- Prognostic Stage II Breast Cancer AJCC v8
- Prognostic Stage IIA Breast Cancer AJCC v8
- Prognostic Stage IIB Breast Cancer AJCC v8
- Prognostic Stage III Breast Cancer AJCC v8
- Prognostic Stage IIIA Breast Cancer AJCC v8
- Prognostic Stage IIIB Breast Cancer AJCC v8
- Prognostic Stage IIIC Breast Cancer AJCC v8
- Triple-Negative Breast Carcinoma
- Metastatic Breast Cancer
Interventions
- OTHER
-
Best Practice
Receive standard of care
- OTHER
-
Informational Intervention
Receive reminders
- OTHER
-
Medical Device Usage and Evaluation
Receive a SMRxT smart pill bottle
- OTHER
-
Quality-of-Life Assessment
Ancillary studies
- OTHER
-
Survey Administration
Ancillary studies
Sponsors & Collaborators
-
NRG Oncology
collaborator OTHER -
National Cancer Institute (NCI)
collaborator NIH -
National Institutes of Health (NIH)
collaborator NIH -
Emory University
lead OTHER
Principal Investigators
-
Ilana Graetz, PhD · Emory University Hospital/Winship Cancer Institute
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-10-22
- Primary Completion
- 2023-08-14
- Completion
- 2024-03-06
Countries
- United States
Study Locations
More Related Trials
-
Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer
NCT04373031 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
NCT05852691 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine
NCT03554109 ·Status: WITHDRAWN ·Phase: PHASE2
-
Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy
NCT05978648 ·Status: RECRUITING ·Phase: PHASE2
-
Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer
NCT06268652 ·Status: RECRUITING ·Phase: PHASE3
-
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
NCT05306340 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
NCT05891093 ·Status: RECRUITING ·Phase: PHASE3
-
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
NCT06797635 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
NCT06449222 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer
NCT03839823 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate Patient Reported Outcome (PRO) and Physical Activity in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Endocrine Therapy or Endocrine Monotherapy
NCT04736576 ·Status: COMPLETED ·Phase: NA
-
Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment
NCT05132790 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform
NCT05916755 ·Status: RECRUITING
-
Serplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast Cancer
NCT06394661 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC
NCT06627712 ·Status: RECRUITING ·Phase: PHASE3
-
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
NCT03310957 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB3 in Healthy Male Subjects
NCT02075073 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)
NCT07208149 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer
NCT05996107 ·Status: RECRUITING ·Phase: PHASE1
-
Neoadjuvant Toripalimab and Radiotherapy Treatment in N+ HR+ Breast Cancer
NCT06671262 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of the Use of Text Message Reminders to Take Palbociclib
NCT04216576 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer
NCT03691311 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Ribociclib in Combination With Adjuvant Endocrine Therapy for Patients With Early High-risk HR+HER2- Breast Cancer
NCT06587789 ·Status: RECRUITING
-
A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer
NCT03197935 ·Status: COMPLETED ·Phase: PHASE3
-
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
NCT05827081 ·Status: RECRUITING ·Phase: PHASE3